Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III, 12-Week, Randomized, Active-Comparator-Controlled, Parallel-Group, Double Blind Study in Korea to Assess the Safety and Efficacy of Etoricoxib 30 mg Versus Celecoxib 200 mg in Patients With Osteoarthritis

NCT01554163 is registered in ClinicalTrials.gov with Organon and Co as lead sponsor.

NCT NCT01554163
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01554163 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III, 12-Week, Randomized, Active-Comparator-Controlled, Parallel-Group, Double Blind Study in Korea to Assess the Safety and Efficacy of Etoricoxib 30 mg Versus Celecoxib 200 mg in Patients With Osteoarthritis
Lead sponsor
Organon and Co
Phase
Phase 3
Overall status
Completed
Start date
March 31, 2012
Completion date
March 31, 2013
Enrollment
239 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

osteoarthritis of the knee